Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis.
Two hundred and ninety-six patients were enrolled in a 6-month, open-label tolerability study of enteric-coated naproxen in patients with rheumatoid arthritis (n = 174) and osteoarthritis (n = 122). Thirty percent of the patients were greater than 65 years of age. Under standard clinical prescribing conditions, enteric-coated naproxen 500 mg twice daily and 375 mg twice daily demonstrated an acceptable tolerability profile that was not different from what one would expect with standard naproxen.
Bellamy
N
N
Department of Medicine, University of Western Ontario, London, Canada.
Beaulieu
A
A
Bombardier
C
C
Esdaile
J
J
Huang
S
S
Jovaisas
A V
AV
Khanna
V N
VN
Kraag
G
G
Mehta
D M
DM
Ménard
H A
HA
D000328:Adult; D000367:Age Factors; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D013608:Tablets, Enteric-Coated
D013608:Tablets, Enteric-Coated; D009288:Naproxen